A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia

被引:142
|
作者
Bhavnani, SM
Drake, JA
Forrest, A
Deinhart, JA
Jones, RN
Biedenbach, DJ
Ballow, CH
机构
[1] Millard Fillmore Hosp, Clin Pharmacokinet Lab, Kaleida Hlth, Buffalo, NY 14209 USA
[2] Univ Iowa, Coll Med, Dept Pathol, Iowa City, IA 52242 USA
关键词
enterococcus; resistance; bacteremia; classification and regression tree analysis; nosocomial pathogens;
D O I
10.1016/S0732-8893(99)00136-4
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
National Nosocomial Resistance Surveillance Group participants from 22 hospitals across the United States reviewed medical records for hospitalized patients with vancomycin-resistant enterococcal (VRE) or vancomycin-susceptible enterococcal (VSE) bacteremia to identify risk factors associated with the acquisition of VRE bacteremia, describe genetic traits of VRE strains, and identify factors predictive of clinical outcome. VRE cases were matched to VSE controls within each institution. Multiple logistic regression (LR) and classification and regression tree (CART) analysis were used to probe for factors associated with VRE bacteremia and clinical outcome. A total of 150 matched-pairs of VRE cases and VSE controls were collected from 1995 to 1997. Using LR, the following were found to be highly associated with VRE bacteremia: history of AIDS, positive HIV status, or drug abuse (OR 9.58); prior exposure with parenteral vancomycin (OR 8.37); and liver transplant history (OR 6.75). CART analysis revealed that isolation of Enterococcus faecium, prior vancomycin exposure, and serum creatinine values greater than or equal to 1.1 mg/dl were predictors of VRE bacteremia. Greater proportions of clinical failure (60% versus 40%, P < 0.001) and all-cause mortality (52% versus 27%, P < 0.001) were seen in patients with VRE versus VSE bacteremia. Results from both LR and CART indicated that patients with persisting enterococcal bacteremia, intubation at baseline, higher APACHE II scores, and VRE bacteremia were at greater risk for poor outcome. (C) 2000 Elsevier Science Inc. All rights reserved.
引用
下载
收藏
页码:145 / 158
页数:14
相关论文
共 50 条
  • [1] Risk factors for development of vancomycin-resistant enterococcal bacteremia among VRE colonizers A retrospective case control study
    Kaya, Abdurrahman
    Kaya, Sibel Yildiz
    Balkan, Ilker Inanc
    Bayramlar, Osman Faruk
    Mete, Bilgul
    Saltoglu, Nese
    Aygun, Gokhan
    Tabak, Omer Fehmi
    WIENER KLINISCHE WOCHENSCHRIFT, 2021, 133 (9-10) : 478 - 483
  • [2] Risk factors for development of vancomycin-resistant enterococcal bacteremia among VRE colonizersA retrospective case control study
    Abdurrahman Kaya
    Sibel Yıldız Kaya
    Ilker Inanç Balkan
    Osman Faruk Bayramlar
    Bilgül Mete
    Neşe Saltoglu
    Gökhan Aygün
    Ömer Fehmi Tabak
    Wiener klinische Wochenschrift, 2021, 133 : 478 - 483
  • [3] Mortality due to vancomycin-resistant enterococcal bacteremia versus vancomycin-susceptible enterococcal bacteremia: An ecological analysis
    Hurley, JC
    CLINICAL INFECTIOUS DISEASES, 2005, 41 (10) : 1541 - 1542
  • [4] Case-case-control study on factors associated with vanB vancomycin-resistant and vancomycin-susceptible enterococcal bacteraemia
    Cheah, Agnes Loo Yee
    Peel, Trisha
    Howden, Benjamin P.
    Spelman, Denis
    Grayson, M. Lindsay
    Nation, Roger L.
    Kong, David C. M.
    BMC INFECTIOUS DISEASES, 2014, 14
  • [5] Case-case-control study on factors associated with vanB vancomycin-resistant and vancomycin-susceptible enterococcal bacteraemia
    Agnes Loo Yee Cheah
    Trisha Peel
    Benjamin P Howden
    Denis Spelman
    M Lindsay Grayson
    Roger L Nation
    David CM Kong
    BMC Infectious Diseases, 14
  • [6] An analysis of treatment of patients with vancomycin-resistant enterococcal bacteremia
    Feldman, RJ
    Paul, SM
    Silber, JL
    Cody, RP
    Noveck, H
    Weinstein, MP
    INFECTIOUS DISEASES IN CLINICAL PRACTICE, 1996, 5 (07) : 440 - 445
  • [7] Vancomycin-resistant and vancomycin-susceptible enterococcal bacteremia: Comparison of clinical features and outcomes
    Lucas, GM
    Lechtzin, N
    Puryear, DW
    Yau, LL
    Flexner, CW
    Moore, RD
    CLINICAL INFECTIOUS DISEASES, 1998, 26 (05) : 1127 - 1133
  • [8] Case-control study of risk factors for the development of enterococcal bacteremia
    Caballero-Granado F.J.
    Becerril B.
    Cisneros J.M.
    Cuberos L.
    Moreno I.
    Pachón J.
    European Journal of Clinical Microbiology and Infectious Diseases, 2001, 20 (2): : 83 - 90
  • [9] Case-control study of risk factors for the development of enterococcal bacteremia
    Caballero-Granado, FJ
    Becerril, B
    Cisneros, JM
    Cuberos, L
    Moreno, I
    Pachón, J
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2001, 20 (02) : 83 - 90
  • [10] Comparison of linezolid and daptomycin for the treatment of vancomycin-resistant enterococcal bacteremia
    Narayanan, Navaneeth
    Rai, Rena
    Vaidya, Parth
    Desai, Avani
    Bhowmick, Tanaya
    Weinstein, Melvin P.
    THERAPEUTIC ADVANCES IN INFECTIOUS DISEASE, 2019, 6